Ignite Creation Date:
2024-05-06 @ 8:20 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06344247
Status:
RECRUITING
Last Update Posted:
2024-04-03
First Post:
2024-03-17
Brief Title:
Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease
Sponsor:
RenJi Hospital
Organization:
RenJi Hospital
Study Overview
Official Title:
Comparison of the Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Obese Patients With Kidney Disease a Single Center Prospective Exploratory Study
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial is to exploring the changes in 24-hour urinary protein and renal function in obese patients with kidney disease after the application of sodium glucose cotransporter 2 inhibitors SGLT2i and glucagon like peptide-1 receptor agonists GLP-1RA
Eligible patients were randomly and non-blindly allocated to four groups in a 1111 ratioThe first group is the optimized treatment group and patients in this group maintain the maximum dosemaximum tolerated dose of RAS blocker therapy
The second group is the optimized treatment SGLT2i group Participants in this group are titrated to the target dose 10 mg qd in combination with dapagliflozin on the basis of optimized treatment
The third group is the optimized treatment GLP-1RA group Participants in this group will be titrated to the target dose 1mg qw in combination with semaglutide on the basis of optimized treatment
The last group is the optimized treatment SGLT2i GLP-1RA treatment group that is based on the optimized treatment combined with dapagliflozin titrated to the target dose 10 mg qd and semaglutide titrated to the target dose 1 mg qw
Eligible patients were randomly and non-blindly allocated to four groups in a 1111 ratioThe first group is the optimized treatment group and patients in this group maintain the maximum dosemaximum tolerated dose of RAS blocker therapy
The second group is the optimized treatment SGLT2i group Participants in this group are titrated to the target dose 10 mg qd in combination with dapagliflozin on the basis of optimized treatment
The third group is the optimized treatment GLP-1RA group Participants in this group will be titrated to the target dose 1mg qw in combination with semaglutide on the basis of optimized treatment
The last group is the optimized treatment SGLT2i GLP-1RA treatment group that is based on the optimized treatment combined with dapagliflozin titrated to the target dose 10 mg qd and semaglutide titrated to the target dose 1 mg qw
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None